A 48-year-old woman receiving combined ipilimumab plus nivolumab treatment for metastatic melanoma in a clinical study (CheckMate 401) was admitted to the Karolinska University Hospital with fever, nose-bleeds, easy bruising and fatigue. She had received four courses with the combination treatment followed by five courses of nivolumab, the last course was given three days prior the admission. Absolute neutrophil count was <0.1 x10 9 /L, platelet count <5 x10 9 /L and hemoglobin level 115 g/L (suppl. 
Focally, stromal edema was noted without signs of fibrosis (Fig1B). Daily treatment with prednisone (1 mg/kg), and granulocyte colony-stimulating factor (G-CSF) was initiated. In protective isolation, the patient received standard antibacterial, antifungal and antiviral treatment and after her second day of admission she had no signs of infections. She received antifibrinolytic treatment with tranexamic acid and repeated platelet transfusions. Since there were no signs of recovery in her pancytopenia, arrangements were made to initiate aplastic anemia treatment with anti-thymocyte globulin (ATG), which also has been used to treat ipilimumab-induced hepatitis [1, 2] . However, at the eleventh day of hospitalization she suffered a brain hemorrhage with a rapid fatal outcome. Postmortem examination revealed a large intracerebral hemorrhage but no signs of brain/leptomeningeal metastases or vascular disease, hence the hemorrhage most likely resulted from the persistent thrombocytopenia. Immune checkpoint blockade with PD-1 and CTLA-4 inhibitors have proven effective in the treatment of metastatic melanoma and also of several other tumors [3] . Combination therapy with PD-1 inhibitor nivolumab and CTLA-4 inhibitor ipilimumab further improves progression-free survival in patients with metastatic melanoma, however the combination therapy increases the risk of immune-related adverse events, in particular diarrhea/colitis, hepatitis, pruritus/rash and endocrine dysfunction [4] . To the authors' knowledge, this is the first reported case of aplastic anemia with a lethal outcome, induced by ipilimumab and nivolumab combination therapy. In the summary of product characteristics (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003985/WC500189765.pdf), grade 3-4 anemia, neutropenia and thrombocytopenia were reported in 2.8%, 0.7% and 1.2% of patients treated with nivolumab plus ipilimumab (n=448). Furthermore, there have been reports of cases with checkpoint blockade induced cytopenias [4, 5] . Collectively, this indicates that in a small proportion of patients receiving these treatments, bone marrow suppression occurs, in some cases probably resulting from T-cell activation against early hematopoietic progenitors. Our case illustrates the importance of detecting low peripheral blood counts timely in patients on 
